94.15
Merus N V stock is traded at $94.15, with a volume of 13.74M.
It is up +0.51% in the last 24 hours and up +43.00% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$93.67
Open:
$93.62
24h Volume:
13.74M
Relative Volume:
9.90
Market Cap:
$7.12B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-23.84
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+38.01%
1M Performance:
+43.00%
6M Performance:
+123.69%
1Y Performance:
+88.45%
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MRUS
Merus N V
|
94.15 | 7.10B | 35.93M | -244.56M | -157.31M | -3.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-17-25 | Initiated | Barclays | Overweight |
Aug-25-25 | Initiated | Alliance Global Partners | Buy |
Feb-13-25 | Initiated | Piper Sandler | Overweight |
Feb-07-25 | Initiated | Wells Fargo | Overweight |
Nov-21-24 | Initiated | Goldman | Buy |
Oct-24-24 | Initiated | UBS | Buy |
Mar-28-24 | Initiated | Truist | Buy |
Mar-04-24 | Reiterated | Needham | Buy |
Nov-02-23 | Initiated | Canaccord Genuity | Buy |
Aug-21-23 | Initiated | TD Cowen | Outperform |
Aug-02-22 | Initiated | Stifel | Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Feb-10-22 | Initiated | Needham | Buy |
Nov-17-21 | Resumed | Guggenheim | Buy |
Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
Apr-08-21 | Initiated | William Blair | Outperform |
Mar-16-21 | Initiated | SVB Leerink | Outperform |
Jun-26-20 | Initiated | H.C. Wainwright | Buy |
May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-20-19 | Resumed | Guggenheim | Buy |
Jun-28-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Resumed | Guggenheim | Buy |
Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-27-19 | Initiated | Berenberg | Buy |
Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
Jun-13-16 | Initiated | Citigroup | Buy |
Jun-13-16 | Initiated | Guggenheim | Buy |
Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V.MRUS - The AI Journal
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS) - PR Newswire
Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab - Latham & Watkins LLP
Genmab Nears Deal to Buy Cancer Drugmaker Merus - MSN
This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
MRUS Analyst Rating Update: Guggenheim Downgrades to Neutral | M - GuruFocus
MRUS Analyst Rating Update: Canaccord Genuity Adjusts PT and Rat - GuruFocus
Merus (MRUS) Sees Rating Downgrade and Target Price Raise by Wells Fargo | MRUS Stock News - GuruFocus
Merus (MRUS) Receives Rating Downgrade by LifeSci Capital | MRUS Stock News - GuruFocus
Barclays Downgrades MRUS, Lowers Price Target Amid Market Adjustments | MRUS Stock News - GuruFocus
Merus (MRUS) Sees Downgrade from UBS with Raised Price Target | MRUS Stock News - GuruFocus
Merus (NASDAQ:MRUS) Receives "Market Perform" Rating from Lifesci Capital - MarketBeat
Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112 - MarketScreener
BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110 - MarketScreener
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - Stocktwits
Merus (NASDAQ:MRUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
Genmab Bets Big On Cancer With $8 Billion Merus Deal - Finimize
Merus Reaches Analyst Target Price - Nasdaq
How big funds are accumulating Merus N.V. (2GH) stock2025 Sector Review & Proven Capital Preservation Methods - newser.com
MRUS Stock Downgraded: HC Wainwright & Co. Lowers Price Target | - GuruFocus
Genmab to acquire Merus shares for $8bn - Yahoo Finance
Barclays downgrades Merus stock to Equalweight, cuts price target on valuation - Investing.com
Guggenheim downgrades Merus stock to Neutral following Genmab acquisition - Investing.com
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - AD HOC NEWS
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction - Yahoo Finance
EQT Is Shareholder in Merus, Acquired by Denmark's Genmab - MarketScreener
Merus stock rating downgraded by UBS after Genmab acquisition - Investing.com India
Genmab to acquire Merus for $8 billion in cash deal By Investing.com - Investing.com Australia
What’s the recovery path for long term holders of Merus N.V.Market Volume Report & Smart Money Movement Alerts - newser.com
Is Merus N.V. building a consolidation base2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Genmab to acquire Merus for $8 billion in cash deal - Investing.com
Genmab swallows Merus in US$8bn deal - European Biotechnology Magazine
Genmab adding late-stage bispecific in $8B Merus acquisition - BioWorld MedTech
Mid Cap Stocks To ConsiderSeptember 29th - MarketBeat
Will Merus N.V. stock see PE expansionLong Setup & Risk Adjusted Swing Trade Ideas - newser.com
Merus N.V. Stock: Analyzing Recent Fluctuations - timothysykes.com
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes - FinancialContent
Leadership Changes and Bold Moves Shake Global Drugmakers - Devdiscourse
Merus (MRUS) Experiences Surge with Significant Stock Price Incr - GuruFocus
Genmab’s $8B Merus takeout is latest push toward full ownership of programs - biocentury.com
Can Merus Sustain The Leap? - StocksToTrade
Transcript : Genmab A/S, Merus N.V.M&A Call - MarketScreener
MRUS: Truist Securities Downgrades Rating, Raises Price Target | MRUS Stock News - GuruFocus
Promising Medical Stocks To Keep An Eye OnSeptember 29th - MarketBeat
Genmab to Acquire Merus in $8 Billion Biotech Deal - USA Herald
MRUS Shares Surge Amid Acquisition Talks - timothysykes.com
4 Firms Advise On Genmab's $8B Merus Acquisition Plan - Law360
HC Wainwright Downgrades Merus to Neutral From Buy, Price Target at $97 - MarketScreener
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
A&O Shearman advises Genmab on its proposed USD8 billion acquisition of Merus - A&O Shearman
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):